Abstract 17808: Fasting Levels of High-sensitive Growth Hormone in Males are Associated to Carotid Intima Media Thickness and are Reduced by Treatment With Fluvastatin
Introduction: Growth hormone (GH) has been linked to cardiovascular disease and lipid metabolism but the exact mechanisms of this association are still unclear.
Objectives: We here test if GH is cross-sectionally associated to carotid intima media thickness (IMT) and whether treatment with fluvastatin have any effects on the fasting level of GH in a randomized controlled trial of carotid IMT progression.
Methods: We examined the association between GH and IMT in 4425 individuals (aged 46-68 years) included in the baseline examination (1991-1994) of the Malmö Diet and Cancer cardiovascular cohort (MDC-CC). From that cohort we then studied 472 individuals (aged 50-70 years) who also participated (1994-1999) in the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS), a randomized, double blind, placebo-controlled, single-center clinical trial. Using multivariate linear regression models we related the change in GH-levels at 12 months compared to baseline to treatment with fluvastatin.
Results: In MDC-CC fasting values of GH exhibited a positive cross-sectional relation to the IMT at the carotid bifurcation after adjustment for traditional cardiovascular risk factors (p=0.002). In a gender-stratified analysis the association were positive and significant for males (p=0.005), but not for females (p=0.09). In males in BCAPS treated with fluvastatin there tended to be a greater reduction of GH after 12 months when compared to subjects not receiving fluvastatin (p=0.05) (Table). Fasting levels of GH did not interact with the different treatment regimes’ effect on the IMT.
Conclusions: We here demonstrate that higher fasting levels of GH are associated to thicker IMT in the carotid bulb and that statin treatment may reduce fasting levels of GH in males. Our results are in line with previous results with GH being associated to cardiovascular disease. The effects of statin treatment on GH are small and need to be confirmed in a larger trial.
Author Disclosures: E. Hallengren: None. P. Almgren: None. M. Rosvall: None. G. Östling: None. M. Persson: None. A. Bergmann: Employment; Significant; Sphingotec GmbH. Ownership Interest; Significant; Sphingotec GmbH. J. Struck: Employment; Significant; Sphingotec GmbH. Ownership Interest; Significant; Sphingotec GmbH. G. Engström: Employment; Significant; Former employee Astra Zeneca. B. Hedblad: None. O. Melander: None.
- © 2015 by American Heart Association, Inc.